Hormones and Agents Affecting Hormonal Mechanism: Antidiabetic Agents: Others
IVICT1 “Victoza Pen injection” 6 mg/ml; 3 ml/pen
適應症：第2 型糖尿病。當患者已接受口服降血糖藥物，及/或基礎胰島素治療仍未達理想血糖控制時，與口服降血糖藥物及/或基礎胰島素併用。
Usual dose:
Diabetes mellitus type II:intial, 0.6 mg subQ every day for 1 week; this dose is to reduce gastrointestinal symptoms during titration and is not effective for glycemic control. Maintenance, 1.2 mg subQ once daily; may increase to 1.8
mg/day if needed; MAX 1.8 mg/day.
Weight maintenance regimen, adjunct to calorie-restricted
diet and exercise:intial, 0.6 mg subQ once daily; increase weekly in increments of 0.6 mg/day until maintenance dose of 3 mg subQ once daily is reached.
Dose adjustment:
Renal impairment, Liver disease: None
Concomitant insulin secretagogues: consider reducing insulin
secretagogue dose by half.
Use with insulin is not recommended.
Gastrointestinal adverse effects: if next dose titration is not
tolerated, may delay titration for 1 week; if 3 mg dose is not
tolerated, discontinue use.
Adverse effect: Hypoglycemia, Constipation, Diarrhea,
Nausea,Vomiting, Headache Upper respiratory infection,
Cholelithiasis, Suicidal thoughts, Angioedema, Breast cancer
健保使用規範：
5.1.3.2 Liraglutide(如Victoza) (101/10/1、105/8/1)
1.限用於已接受過最大耐受劑量的metformin及/或sulfonylurea類藥物仍無法理想控制血糖之第二型糖尿病患者。
2.當患者已接受口服降血糖藥物，及/或基礎胰島素治療仍未達理想血糖控制時，與口服降血糖藥物及/或基礎胰島素併用。
3.本藥品不得與DPP-4抑制劑、SGLT-2抑制劑併用。